RESUMO
Herbal medicines made from the bark of the Cinchona tree, and later quinine, have been widely used for centuries to treat medical conditions such as tropical malaria. More recently, chloroquine (CQ) and its synthetic derivatives have been used as antimalarials and to treat systemic lupus erythematosus, rheumatoid arthritis, and in the past 14 months or so, COVID-19 pneumonia. Anecdotal evidence and the erratic covering through social media of its potential efficacy in the treatment of COVID-19 pneumonia have resulted in the widespread off-label use of CQ in South Africa and worldwide. This study aimed to show that access to CQ as a chronic medication for rheumatic and musculoskeletal diseases was limited during the COVID-19 pandemic, and that this resulted in an increased incidence of flares in these patients, affecting their morbidity and potentially leading to mortality.
Assuntos
Cloroquina/farmacologia , Reumatologia/normas , Instituições de Assistência Ambulatorial/organização & administração , Instituições de Assistência Ambulatorial/estatística & dados numéricos , Antirreumáticos/farmacologia , Antirreumáticos/uso terapêutico , Cloroquina/uso terapêutico , Humanos , Doenças Musculoesqueléticas/tratamento farmacológico , Doenças Reumáticas/tratamento farmacológico , Reumatologia/métodos , Reumatologia/estatística & dados numéricos , Tratamento Farmacológico da COVID-19RESUMO
Lower back pain is one of the most common symptomsand the most common musculoskeletal problemseen by general practitioners. Iti s also a common cause of disability and an expensive condition in terms of economic impact because of absenteeism. This article discusses an approach to this common symptom and how to distinguish the benign, mechanical type of back pain from the more sinister, but less frequently encountered, inflammatory back pain.